Table 1.
Patient characteristics of patients in the fluticasone, azithromycin, and montelukast trial and retrospective Fred Hutchinson Cancer Research Center cohorts
| FAM Cohort (n = 36) | FHCRC Cohort (n = 46) | |
|---|---|---|
| Age at allogeneic hematopoietic cell transplant, yr, median (range) | 53 (23–70) | 47 (13–67) |
| Months to bronchiolitis obliterans syndrome, median (range) | 17.9 (5.0–131) | 13.9 (5.0–39.9) |
| Sex, n (%) | ||
| Female | 17 (47) | 16 (35) |
| Male | 19 (53) | 30 (65) |
| Cytomegalovirus, n (%) | ||
| Negative | 16 (50) | 20 (43) |
| Positive | 16 (50) | 26 (57) |
| Conditioning, n (%) | ||
| Nonmyeloablative | 14 (39) | 18 (39) |
| Myeloablative | 22 (61) | 28 (61) |
| Stem cell source, n (%) | ||
| Peripheral blood | 31 (86) | 42 (91) |
| Bone marrow | 5 (14) | 4 (9) |
| Donor, n (%) | ||
| Related | 21 (58) | 24 (52) |
| Unrelated | 15 (42) | 22 (48) |
Definition of abbreviations: FAM = fluticasone, azithromycin, montelukast; FHCRC = Fred Hutchinson Cancer Research Center.